Safety and Efficacy of Golimumab Administered Intravenously in Adults with Ankylosing Spondylitis: Results through Week 28 of the GO-ALIVE Study
Deodhar A, Reveille JD, Harrison DD, Kim L, Lo KH, Leu JH, Hsia EC. Safety and efficacy of golimumab administered intravenously in adults with ankylosing spondylitis: results through week 28 of the GO-ALIVE study. J Rheumatol 2017; doi:10.3899/jrheum.170487. In Figure 2 of this article, the legend for Panel C is incorrect. The legend should read, “Placebo → Golimumab 2 mg/kg (n = 103)”.
This correction applies only to the December 15 First Release. The correct figure appears online and will appear in the March print edition.
